Mice sensitized with D-galactosamine (GaIN) and challenged with recombinant murine tumor necrosis factor a (TNFa) developed severe apoptotic and secondary necrotic liver injury as assessed by histology, measurement of cytosolic DNA fragments, and determination of liver specific enzymes in plasma. Pretreatment with recombinant human interleukin-1p (IL-1) rendered mice insensitive to this TNFa toxicity. Coadministration of the liver-specific transcriptional inhibitor GaIN with ILl prevented the development of tolerance, implicating de novo synthesis of liver specific proteins in the induction of tolerance. Pretreatment of mice with IL-1 resulted in elevated levels of nitrite/nitrate in serum and in enhanced nitric oxide synthase (NOS) activity in liver cells isolated from these animals. In addition, pharmacological doses of the nitric oxide (NO) donor sodium nitroprusside conferred complete protection against TNFainduced liver injury in galactosamine-sensitized mice, suggesting a possible link between IL-1-and NO-induced protection. However, prevention of NO-synthesis by ~-monomethyl-L-arginine (NMMA) did not abolish IL-1-induced tolerance to TNFa in vivo. Cytotoxicity of TNFa to isolated hepatocytes sensitized with actinomycin D (ActD) was not significantly altered by inhibition of endogenous nitrite release. Also, enhanced NO production elicited in vitro by glycerol trinitrate or ex vivo by pretreatment with IL-1 had no significant effect in this system. We conclude that IL-1-and NO-induced protection of mice against TNFa-mediated liver damage follow distinct pathways.
Bacterial endotoxins Oipopolysaccharides [LPS])
, as well as constituents from gram-positive bacteria, fungi, protozoa, or viruses, exert their proinflammatory effects by inducing the production of a variety of endogenous mediators in the host. Tumor necrosis factor a (TNFa) has been recognized as one of the key inflammatory mediators in various experimental settings and has been shown to mediate lethal shock and multiorgan failure (for review see reference 1) .
Various animal models have been developed to study organ injury induced by TNFa. We and others have used mice sensitized to LPS or TNFa by transcriptional inhibitors such as D-galactosamine (GaIN)2,3 or actinomycin D (ActD). 4 In analogy to data from experiments carried out in vivo, ActD has been shown to sensitize cell lines up to 10,OOO-fold towards TNFa. An essential feature of the in vivo models is that during transcriptional inhibition otherwise subtoxic doses of TNFa result in a relatively selective liver damage which allows quantitative assessment of TNFa-toxicity by measurement of plasma enzymes. 3 In the GaIN model, animals can be completely desensitized to an otherwise lethal challenge of either LPS or TNFa by pretreatment with LPS, TNFa, or interleukin-1f3 (IL-1).5 Of these agents, IL-1 was shown to be the most potent tolerance-inducing agent to TNFa challenge in GaIN-sensitized animals. 5 Although the mediators and mechanisms of tolerance may have important clinical implications, the phenomenon is not well understood. Tolerance is best characterized at the level of macrophages, which release a reduced spectrum of mediators upon LPS stimulation after desensitization with LPS. 6 However, this mechanism alone is unlikely to account for tolerance to direct administration of TNFa in vivo. 5 Circumstantial evidence suggests the involvement of nitric oxide (NO) (for review see reference 7), a pleiotropic endogenous mediator, in the development of tolerance to LPS-or cytokine-induced toxicity. Stimulation with cytokines was shown to induce NO production by endothelial cells, 8 macrophages, 9 hepatocytes, 10-12 and Ito cells. 13 Moreover, it was shown that endogenously produced NO reduced organ injury or mortality in various models of septic organ failure and shock, such as endotoxin-induced liver damage, glomerular thrombosis, or endotoxin shockY-17 1829 First publ. in: Hepatology 22 (1995) , 6, pp. Because IL-l is both a strong inducer of NO synthases (NOS)18,19 and a potent agent for induction of tolerance, 5, 20, 21 in this study we investigated whether there is a causal relation between IL-l-mediated tolerance to TNFa-induced liver damage and NO formation. The first aim of this study was to check whether tolerance induction results in an increase in NOS-activity. Secondly, we examined whether or not NOS induction was responsible for IL-l-mediated tolerance to TNFa in GaIN-sensitized mice, i.e., in a model in which toxicity is unlikely to be primarily initiated by LPS-induced endogenous cytokine production.
MATERIALS AND METHODS
Animal Experiments. Male Bagg Albino/c mice were supplied by the animal house of the University of Konstanz, Germany. Animals were kept at 22°C and 55% relative humidity in a 12-hour day-night rhythm with free access to food (Altromin 1313; Altromin Co., Lage, Germany) and water. 16 hours before in vivo experiments food was withdrawn. For hepatocyte isolation, fed Bagg Albino/c mice were used. All animals received humane care in compliance with the guidelines of the local authorities.
Treatment Schedules. All substances were administered in pyrogen-free saline. LPS (Roth, Karlsruhe, Germany), sodium nitroprusside (SNP) (Fluka, Buchs, Switzerland), and GaIN (Roth) were injected intraperitoneally in a volume of 200 p,L, recombinant human IL-1f3 (a gift from Dr K. Vosbeck, Ciba-Geigy, Basel, Switzerland), recombinant murine TNFa (a gift from Dr Adolf, Bender & Co., Vienna, Austria) and NMMA (Sigma Chemical Co., St. Louis, MO) were injected intravenously in a volume of 300 p,L. Animals were killed by cervical dislocation 8 hours after challenge, and blood was withdrawn by cardiac puncture into heparinized syringes.
DNA-Fragmentation. Livers were perfused for 10 seconds with cold perfusion buffer (50 mmollL phosphate, 120 mmol/ L NaCI, 10 mmollL ethylenediaminetetraacetic acid, pH 7.4), before they were excised. One slice of the large anterior lobe was immediately fIxed in 4% formalin for histological studies. The remaining parts of the liver were disintegrated with three strokes of an Elvehjem type homogenizer. The 20% homogenate (in perfusion buffer) was centrifuged at 13,000g for 20 minutes. The supernatant was further diluted 250-fold. DNA fragmentation was quantifIed by measuring cytosolic oligonucleosome-bound DNA using an enzyme-linked immunosorbent assay (ELISA) kit (Boehringer, Mannheim, Germany).22 Briefly, the cytosolic fraction (13,000g supernatant) from about 75 p,g of liver was used as antigen source in a sandwich ELISA with a primary antihistone antibody coated to the microtiter plate and a secondary anti-DNA antibody coupled to peroxidase.
Histology. Formalin-fIxed liver slices were imbedded in paraplast. 2-to 3-p,m sections were stained with hematoxylinl eosin.
Cell Culture and Incubation Conditions. Hepatocytes were isolated from 12-week-old male Bagg Albino/c mice by the two-step collagenase perfusion method according to Seglen,23 modifIed by Klaunig et al.24 Nonparenchymalliver cells, containing about 50% macrophages, were prepared by differential centrifugation according to Doolittle 
Absorbancecontrol
TNFa Assay. TNFa in liver cell supernatants was determined essentially as described in Espevik and NissenMeyer,29 using recombinant murine TNFa as a standard.
Nitrite Determination in Cell Culture Supernatants. For determination of nitrite release cells were incubated for 20 hours in RPMI 1640 medium without phenol red. Culture supernatants were assayed for nitrite by the Griess reaction: briefly, 200 p,L culture supernatant were transferred to 96-well microtiter plates, 20 p,L sulfanilamide (1% in 1.2 mollL HCI, Sigma Chemical Co.), and 20 p,LN-(l-naphthyl) ethylendiamine (0.1% in H 2 0, Sigma Chemical Co.) were added and absorbance was read after 3 minutes' incubation time at 5601 690 nm on an ELISA-reader. The nitrite content in the culture supernatant increased linearly within the time span of 20 hours investigated.
Nitrite Determination in Serum. Nitrite in serum was measured essentially according to the method of Misko et al,30 using the Griess assay instead of the fluorimetric assay described. Briefly, plasma obtained by cardiac puncture into heparinized syringes was fIltered through an Ultrafree-MC microcentrifuge fIlter unit (Millipore, Bedford, MA) for 1 hour at 14,000 rpm to remove hemoglobin released by cell lysis, which might interfere with the colorimetric assay. Because nitrite in serum is mostly oxidized to nitrate by reaction with the iron-heme center ofhemoglobin, the resulting nitrate was fIrst reduced to nitrite by incubation with nitrate reductase from aspergillus species (Sigma Chemical Co). tion at room temperature, the reaction was terminated by dilution with 50 f-LL of distilled water. The whole reaction volume was transferred to 96-well microtiter plates, 10 f-LL sulfanilamide (1% in 1.2 mollL HCl), and 10 f-LL N-(l-naphthyl) ethylenediamine (0.1% in H 2 0) were added and absorbance was read after 3 minutes' incubation time at 560/ 690 nm on an ELISA reader.
Statistics. Data from in vivo experiments are given as mean ± SE M, all other data as mean ± SD. Data for transaminases and DNA-fragmentation were analyzed by nonparametric analysis of variance (Kruskal-Wallis). Where there were differences among the groups (P < .05), these were subjected to one-sided nonparametric multiple comparisons of the control against all other groupS.31 Statistical analysis of nitrite/nitrate concentrations (Tables 2 and 3 ) was done using the parametric Waller-Duncan test. P < .05 was considered to be significant.
RESULTS

IL-I-Induced Tolerance to GaIN/TNF-Mediated Liver
Damage. Intravenous administration of recombinant murine TNFa (10 p,glkg) to GaIN-sensitized male BALB/c mice induced severe necrotic liver damage as determined by elevated plasma levels of liver enzymes 8 hours after challenge (Fig. 1) . Apoptotic changes preceded liver necrosis by several hours. Mter 5 hours, . oligonucleosomal cytosolic DNA-fragments in livers of GalNITNF challenged mice were increased 2.9 ± 0.7-fold compared with livers treated with GaIN only. Eight hours after challenge, i.e., at the time when blood was withdrawn for assessment of liver injury by clinical chemistry, DNA-fragmentation was increased 3.6 ± O.4-fold § compared with controls (data ± SEM, n = 3, §P < .05 vs. GaIN-treated control). Histological examination confirmed these findings and their interpretation; 3.5 hours after injection of TNFa to GaINsensitized mice, hyperchromatic nuclear membranes and formation of apoptotic bodies were observed. Eight hours after TNF, numerous apoptotic bodies were identified between necrotic hepatocytes (Fig. 2) . In contrast, pretreatment of the animals with 10 p,glkgrecombinant human IL-1f3 intravenously 4 hours before challenge led to a completely refractory state with respect to TNFa-induced cytotoxicity in GaIN-sensitized mice; i.e., no significant transaminase release into plasma occurred at 5 hours or at 8 hours after TNFa administration ( Fig. 1) and DNA-fragmentation was not significantly increased at 5 hours (130 ± 10% of GaIN control) and 8 hours (110 ± 10%). Nevertheless, numerous infiltrating neutrophils were present in the liver of IL-1-pretreated mice 8 hours after challenge with GaIN and TNF (Fig. 2) . IL-1-pretreated mice went through a period of illness characterized by reduced motility and piloerection. However, the animals recovered from these symptoms within a few hours. When we varied the interval between IL-1 pretreatment and challenge, we found that tolerance started as early as 1 hour after IL-1 pretreatment and lasted for at least 48 hours (data not shown).
Prevention of IL-l Induced Tolerance by Inhibition
of Hepatic Transcription. Cytokine producing macrophages were not rendered refractory by IL-1 pretreatment. In fact, spontaneous TNFa release from liver macrophages prepared from tolerant mice was significantly enhanced (1.2 ± 0.8 ng/10 6 cells) compared with cells from untreated controls (0.7 ± 0.2 ng/10 6 cells). LPS-induced TNFa-release from IL-1-pretreated mice was not significantly different from that released from Kupffer cells of control mice (9.0 ± 1.8 vs. 9.9 ± 2.8 ng/ 10 6 cells). These data suggest that tolerance induced by IL-1 may be confined to the target of TNFa-mediated cytotoxicity, i.e., liver parenchymal cells. To study the role of hepatic transcription in the development of tolerance, the liver-specific transcriptional inhibitor GaIN was applied together with IL-1. This treatment protocol prevented IL-1-induced tolerance to a subsequent challenge with GaIN and TNFa (Fig. 1), i.e., we observed fulminant hepatic failure caused by GalNITNFa in spite of a preceding treatment with a dose of IL-1 that otherwise would have provided complete protection against TNFa challenge.
Protection Against GaIN/TNFa-Induced Liver Damage by Administration of SNP. Liver NOS is one of the putatively protective proteins 14 -17 known to be induced by IL_1. 10 ,12,19 To study possible participation of NO in the development of tolerance, we first tested the efficacy of the pharmacological NO donor SNP against liver damage induced by TNFa in GaIN-sensitized mice. GaIN-sensitized mice treated with SNP (1.7 mg/ kg, 15 minutes before challenge) were protected against liver damage induced by recombinant murine TNFa (10 p,glkg) (Table 1) . Thus, endogenous NO pro-duction from exogenous precursors has the potential to protect against TNFa-mediated toxicity. Although the animals showed very pronounced hypotension and vasodilatation over a period of 20 minutes after SNP administration, no elevated nitrate/nitrite levels were detectable in plasma 15 minutes or 2 hours after injection of SNP. This is explained by the fact that the maximal attainable NO concentration (9 p,mol/L) after this dose of SNP (170 nmol/mouse) is below the detection limit of the Griess assay. IL-I-Induced Endogenous NO Production. Because pharmacologically delivered NO provided protection against TNFa toxicity in vivo, we checked whether NO was produced endogenously upon treatment of mice with IL-l. Male BALB/c mice were injected with either saline or IL-l (10 p,g/kg). Serum nitrite/nitrate levels were elevated 6 hours after administration of IL-l as compared with saline-treated animals ( Table 2) . To identify the source of IL-l-induced endogenous NO production, hepatocyte and nonparenchymalliver cell cultures from IL-l-or saline-treated animals were prepared 4 hours after pretreatment. Endogenous NO production was determined by measuring the amount of nitrite released into the culture supernatant. Hepatocytes were left untreated or were further stimulated by incubation with LPS (10 p,g/mL) or IL-l (50 ng/mL). Hepatocytes isolated from saline-treated animals released less than 1 nmol nitrite/l0 6 cells within 20 hours whereas in vivo pretreatment with IL-l led to an increased spontaneous ex vivo nitrite production in liver cell cultures by a factor of at least five (Table 3 ). This augmented basal release was further enhanced by more than fourfold when these cells were incubated with IL-l in vitro (Table 3) . To characterize the requirements for induction of NOS activity by IL-l, animals were simul- taneously treated with the transcriptional inhibitor GaIN or with the translational inhibitor cycloheximide, 4 hours before the preparation of hepatocytes. Coadministration of GaIN and IL-1 did not abrogate the subsequent nitrite production from hepatocytes. Cells from these animals showed an even greater spontaneous release of NO that was further increased more than fourfold by in vitro stimulation with IL-1 ( Table 3 ). In contrast, cells from cycloheximideIIL-1-treated animals showed no increased basal or IL-1 inducible release of nitrite compared with controls (Table 3) . When cycloheximide (50 p,mollL) was present in vitro together with the stimulus, the further induction of NOS-activity by IL-1 was completely prevented in all experiments (data not shown). Additional experiments showed that nonparenchymalliver cell cultures prepared from the same mice by differential centrifugation and plastic adhesion produced less than 5% per cell of the nitrite found in hepatocyte cultures, suggesting that the nitrite determined in the above experiments was predominantly derived from hepatocytes.
No Impairment of Tolerance by Inhibition of NOS In
Vivo. To study the relevance of endogenously formed NO to the development of tolerance in vivo, we inhibited endogenous NO production by administration of ~monomethyl-L-arginine (NMMA) (2 X 175 mg/kg) , a competitive inhibitor of NOS. NMMA reduced the elevated nitrate/nitrite levels caused by IL-1 pretreatment to values observed in control animals. However, administration of NMMA caused neither an altered toxicity ofTNFa in vivo nor any modification of the ILl-induced tolerance in GaIN-sensitized mice (Table 2) . Interestingly, injection of GaIN with or without TNFa 4 hours after administration ofIL-1 already prevented the increase of nitrite/nitrate concentrations in serum. Because GaIN is a liver specific transcriptional inhibitor, this suggests that the liver is the major source of IL-1-induced nitrite/nitrate release into plasma.
Absence of Ex Vivo Tolerance. To further explore the mechanisms of IL-1-induced target cell tolerance, we studied whether the state of tolerance induced by IL- 1 in vivo was still present ex vivo in hepatocytes. Liver cells prepared from tolerant and nontolerant mice were compared with respect to their susceptibility to TNFa cytotoxicity after sensitization with the transcriptional inhibitor ActD. In this ex vivo experiment-in contrast to the protection observed that was caused by IL-1 in vivo-hepatocyte death induced by ActDtrNFa occurred to a similar extent regardless of the pretreatment (Fig. 3) . Thus, the difference in spontaneous NO production between hepatocytes from IL-1-pretreated mice and cells from control animals ( Table 3) had no significant influence on the sensitivity of liver cells to TNFa in vitro.
Lack of Correlation Between Nitrite Release and Cytotoxicity of ActDITNFa
In Vitro. The finding that TNF -induced hepatocytotoxicity in ActD pretreated cells occurred independently of hepatocyte NO production was further corroborated by experiments using the NOS inhibitors NMMA or Nw-nitro-L-arginine (0.1 mmollL). In control experiments, these inhibitors were shown to completely block nitrite release from hepatocytes prepared from tolerant mice. Nevertheless, these NOS inhibitors did not significantly affect the cytotoxicity of TNFa in hepatocytes in the presence of ActD (Table 4) . Also, the NO donor glycerol trinitrate neither protected nor sensitized hepatocytes against ActD/ TNFa-induced hepatocytotoxicity (Table 4) .
DISCUSSION
A large variety of experimental models have been used to study possible mechanisms of septic shock and ensuing organ failure. LPS, as the primary initiator of 3 . TNF cytotoxicity on ActD-sensitized hepatocytes from ILl pretreated or control mice. Hepatocytes were prepared 4 hours after pretreatment (10 /-lg/kg IL-1, or salinel. Cells were incubated with 333 nmollL of ActD for 30 minutes before addition of TNF (1.5 to 100 ng/mLl. LDH release was determined after 20 hours of in cubation as an indicator of cell death. Treatment with ActD alone did not induce LDH release significantly higher than that of untreated hepatocytes. Data are expressed as mean ± SD of triplicate incubations. NwNA, 0.1 mmollL; nitroglycerin 55 /-lmollL in 0.1% EtOH) and stimuli was started 4 hours after hepatocyte preparation.
:j: Determined by MTT viability assay after 20 hours' incubation. ActD (333 nmollLl was added 30 minutes before TNFa (15 ng/mLl. Toxicity was compared with hepatocytes only treated with ActD.
§ Amount of nitrite released into the medium in nmol/l0 B cells 20 h after start of incubation. a cytokine response, or TNFa, as a distal mediator of LPS toxicity, also in GaIN-sensitized mice,3 are commonly used to elicit the systemic inflammatory response. However, pretreatment with minute amounts of either one of these agents protects mice from a second, otherwise lethal, challenge. Besides TNFa, a variety of other cytokines, such as IL-lO, transforming growth factor-jJ, or IL-1, have been implicated in tolerance induction. 4 ,5,2o,32 In the present study, we used ILl to induce tolerance to the TNFa challenge in the lowdose model of the GaIN-sensitized mouse. This study design allowed us to investigate mechanisms of target cell tolerance independent of the suppression of TNFa release from macrophages. The dose of TNFa used in our experiments with GaIN-sensitized mice was chosen to cause severe necrotic liver injury at about 8 hours after challenge. This protocol allows us to study acute inflammatory injury of the liver.33 In this model, we found that IL-1 caused tolerance against GalNtrNFa when given at any time between 1 hour and 48 hours before challenge. We chose 4 hours as the pretreatment interval to leave sufficient time between the two doses of GaIN that were administered in some of the experiments (prevention ofIL-1-induced tolerance by inhibition of hepatic transcription).
As with the liver failure observed in the ActDtrNFa model,22 a salient feature of the GalNtrNFa model is apoptotic and secondary necrotic liver cell death. 34 Therefore, we measured both cytosolic DNA fragments and hepatocyte specific enzymes to quantitate organ injury. According to these parameters, IL-1 completely protected mice against both forms of hepatic injury induced by TNFa. Because the development of tolerance could be completely abolished by coadministration of GaIN, which selectively impairs the hepatic RNA synthesis 34 via trapping of uridine nucleotides and subsequent depletion of the uridine triphosphate pool,35 we conclude that IL-l-induced tolerance is an active process requiring hepatic transcription. This view is further corroborated by our finding that cytokine release of Kupffer cells prepared from IL-l-treated, tolerant animals was not impaired compared with controls. Several IL-l-inducible intrahepatic or secretory liver proteins have been described as being associated with the development of tolerance, e.g., manganese superoxide dismutase,36,37,38 or acute phase proteins like ferritin 39 or aracid glycoprotein. 40 These observations imply an active biosynthetic intrahepatic process as a cause of tolerance development.
Another putatively protective protein known to be induced by IL-l is NOS, an enzyme producing the potent vasodilatator NO. l4 -l7 Our finding that NOS activity is increased by incubation of murine liver cell cultures with IL-l in vitro is in agreement with previous findings showing an induction of NOS messenger RNA in rat and human hepatocytes under similar conditions. l2 ,l9 In our experiments, enhancement of NOS activity in murine hepatocytes was suppressed by incubation with cycloheximide, suggesting induction via de novo protein synthesis. In analogy to the in vitro experiment, treatment of mice with IL-l in vivo led to elevated levels of nitrite/nitrate in serum and to an increased NOS activity in liver cells prepared from these animals. However, the induction of NOS under the latter conditions did not render these cells tolerant to the cytotoxic action of TNFa in the presence of ActD. Furthermore, NOS activity ex vivo was still enhanced in cells from IL-l-treated animals in which tolerance induction was blocked by coadministration of GaIN. In contrast to these ex vivo observations, in vivo the administration of GaIN 4 hours after treatment of mice with IL-l prevented the IL-l-induced increase in plasma nitrate/nitrite. Two explanations seem feasible for this obvious difference between our in vivo and ex vivo findings. In contrast to the accumulation of nitrite in vitro, nitrate and nitrite may be eliminated via urinary excretion in vivo, necessitating continous RNA and protein synthesis to maintain elevated nitrate/nitrite plasma levels. Alternatively, the nitrite release ex vivo might be explained by a rapid repletion of cellular uridine pools during the in vitro incubation, i.e., an abolition of a persistent GaIN effect on transcription. In any case, our in vivo and ex vivo experiments provide additional evidence that the phenomenon of tolerance and NOS induction are separate events. Our data confirm that IL-l induces NOS both in vivo and in vitro. However, the induction of NOS and development of tolerance seem to be simultaneous events occurring independently from each other.
The cytotoxicity of TNFa in hepatocyte cultures containing ActD was neither affected by inhibition of nitrite release nor by enhancement of NO-formation by 1835 glycerol trinitrate. These findings suggest that, on the one hand NO is not required for the toxicity of TNF in murine hepatocytes. On the other hand, NO did not prevent cytotoxicity in this in vitro model when present in excess. The lack of protection by exogenously applied NO in this in vitro model compared with the proteCtion seen in vivo may be explained by physiological reactions that cannot take place in vitro such as prevention of ischemiaireperfusion by SNP-induced vasodilatation.
The reason why hepatocytes prepared from IL-ltolerant mice are sensitive to ActDITNFa induced cytotoxicity is not known. It is conceivable that the protection conferred by proteins synthesized in the liver is indirectly mediated through the interaction with extrahepatic cells, e.g., liver-derived proteins such as al acid glycoprotein, may cause the release of anti-inflammatory glucocorticoids from the adrenals. Alternatively, protection might be mediated directly by plasma proteins synthesized by the liver.40 Such proteins may not be present in sufficient amounts in cell cultures.
The role of endogenously produced NO in septic shock and other inflammatory models is not yet clarified. To study the significance of NO in TNFa-induced liver failure in GaIN-sensitized mice and to further investigate the role of endogenously formed NO for the development of tolerance, we examined whether injection of an NO-releasing agent (SNP) in vivo could protect against TNFa toxicity and what effects inhibition of NOS might have on IL-l-induced tolerance. The finding that SNP protected against TNFa-induced hepatotoxicity is consistent with findings in the GaIN/ LPS model where various vasodilatators were protectiveY An increased production of NO is probably responsible for the detrimental decrease in blood pressure seen in septic shock,42,43 and knock-out mice lacking the inducible NOS show decreased sensitivity towards LPS-induced lethality.43,44 Nevertheless, beneficial effects of this mediator in sepsis have also been described. For instance, an aggravation ofLPS-induced hepatic damage in Corynebacterium parvum-sensitized mice by administration of NMMA, a competitive inhibitor of NOS, was reported l4 ,l5 and inhibition of endogenous NO production increased lethality in staphylococcal enterotoxin-B-induced shock in mice. 45 Furthermore, whereas NMMA administered to a patient in septic shock increased blood pressure as expected, it finally led to intravascular coagulation and death. 46 The aggravation of septic complications by inhibition of NO formation on the one hand and the protection against TNFa conferred by SNP on the other hand suggest beneficial effects of endogenously produced NO. However, we observed that NMMA administration did not abolish IL-l-induced tolerance although the increase in serum nitrite/nitrate levels induced by IL-l pretreatment was shown to be completely prevented. This argues against a predominant role of endogenously produced NO in this inflammatory model and against a role of NO in the development of tolerance.
In summary, IL-l pretreatment protected GaIN-sensitized mice against TNFa induced hepatotoxicity. Although IL-l increased NO release of liver cells in vivo and ex vivo and although treatment with the NO donor SNP was protective against TNFa toxicity, endogenously produced NO had no effect on IL-l induced tolerance in vivo nor on TNFa mediated cytotoxicity in vitro in the presence of ActD. We conclude that IL-l induces expression and/or release of tolerance-inducing proteins different from NOS and that increased production of endogenous NO is not the mechanism responsible for tolerance development.
